Drug Profile
Anti-tumour necrosis factor alpha biosimilar - Mabion
Latest Information Update: 05 Aug 2015
Price :
$50
*
At a glance
- Originator Mabion
- Class Antineoplastics; Blood proteins; Glycoproteins; Monokines; Tumour necrosis factors
- Mechanism of Action Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Autoimmune disorders
Most Recent Events
- 22 Jun 2015 Discontinued for Autoimmune disorders in Poland (unspecified route)